Qiming Weekly | Qiming Venture Partners Portfolio Companies: Funding and Updates Vol. 15, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take is worth recording. Qiming Venture Partners will continue to accelerate and empower founders, and we invite you to join us in celebrating the milestone moments of our portfolio companies.
Funding News
Ze'an Biopharmaceutical Closes $40 Million Series A+ Round
Ze'an Biopharmaceutical, a Qiming Venture Partners portfolio company, recently announced it has oversubscribed its Series A+ round, raising $40 million. Since its founding in 2022, Ze'an Biopharmaceutical has raised a total of $90 million. Qiming Venture Partners participated in its Pre-A round, led its Pre-A+ round, and made a follow-on investment in its Series A.
Ze'an Biopharmaceutical focuses on unmet clinical needs in cancer, autoimmune diseases, and other major disease areas, developing novel immunotherapies based on its Myeloid Engager Platform. Proceeds from this round will primarily support Phase 1 clinical studies of its lead candidate LTZ-301, advance IND-enabling work for its second candidate LTZ-232 in pan-solid tumor indications, and fuel early-stage R&D programs and global team expansion.
Major Partnerships
01/
Hesai Technology and KargoBot Deepen Collaboration
Hesai Technology (NASDAQ: HSAI), a Qiming Venture Partners portfolio company, and autonomous trucking technology company KargoBot recently announced a deepened strategic partnership. Hesai's AT1440 — the world's highest line-count, automotive-grade, mass-produced LiDAR — makes its debut on KargoBot's global first future transport robot, and is also integrated into KargoBot's mass-produced L4 autonomous truck platooning solution, helping KargoBot achieve large-scale commercial deployment of autonomous freight operations. This collaboration marks a key step forward for both parties in advancing high-level autonomous driving commercialization.
The AT1440 is powered by Hesai's fourth-generation self-developed chip, employing cutting-edge high-efficiency photosensing and ultra-high parallel processing technology to achieve ultra-long-range detection of 300 meters (at 10% reflectivity). With an angular resolution of 0.05°×0.0125°, it outputs image-grade point clouds with density exceeding current mainstream automotive LiDAR by more than 45 times, precisely identifying small obstacles in complex urban scenarios. With 360° full-scene coverage and zero blind spots, the AT1440 will serve as the core perception hardware enabling KargoBot's fully unmanned freight operations.
02/
Zhipu AI and Shengshu Technology Form Strategic Partnership
Zhipu AI and Shengshu Technology, two Qiming Venture Partners portfolio companies, recently announced they will leverage their respective technical strengths in large language models and multimodal generative models to collaborate on joint R&D, product integration, solution bundling, and industry coordination — jointly advancing domestic large model technology innovation and industrial deployment.
Under the strategic agreement, Zhipu AI's MaaS platform will integrate Shengshu Technology's Vidu API, combining Vidu's video generation capabilities to serve a broader range of developers and enterprise customers. On the solutions front, both parties will draw on their respective strengths to build more competitive technical solutions for key industries. For industry coordination, they will focus on verticals including government and enterprise services, general internet, culture and tourism, advertising and marketing, animation and film, and broadcasting media — jointly building AI innovative applications that meet diverse industry demands and driving scaled deployment in priority sectors.
03/
StepFun and Yuanli Lingji Form Strategic Partnership
StepFun and Yuanli Lingji, two Qiming Venture Partners portfolio companies, formally signed a strategic cooperation agreement. Both parties announced they will leverage their respective advantages to collaborate deeply around multimodal large model technology, intelligent terminal agents, and embodied intelligence scenarios — with the vision of "Reasoning in the real world" to build "RoboAgent" and jointly advance the application of artificial general intelligence (AGI) in the physical world.
Per the cooperation agreement, both parties will collaborate deeply on embodied large model algorithm R&D, multimodal data closed loops, and robotics scenario applications, jointly tackling key technical challenges for RoboAgent deployment in the physical world. Going forward, they plan to co-build a joint laboratory to accelerate technology iteration and commercial validation, and explore long-term collaboration in open-source ecosystems and vertical industries.
04/
Biren Technology and Kehua Data Form Strategic Partnership
Biren Technology, a Qiming Venture Partners portfolio company, and Kehua Data formally signed a strategic cooperation agreement — building on the fruitful results both sides have already achieved in intelligent computing center construction, computing platform development, and industry standard formulation.
Under this collaboration, Kehua Data will fully leverage its strengths in data center infrastructure products and full-lifecycle IDC services, drawing on its multiple self-built large-scale intelligent computing centers nationwide to provide robust computing scenarios for Biren Technology's general-purpose high-performance GPU products. Meanwhile, Biren Technology will fully leverage its technical advantages in general-purpose GPU software and hardware systems to work with Kehua Data in advancing scaled deployment of relevant products in education, finance, intelligent manufacturing, internet, and other industries. Additionally, both parties will establish a strategic cooperation steering group to integrate advantageous resources, build premium industry solutions, and accelerate customer outreach and expansion through joint marketing — setting a benchmark for domestic general-purpose GPU ecosystem cooperation and supporting the sustained vigorous development of the domestic AI chip industry.
05/
Axera and Aptiv Form Partnership
Recently, Qiming Venture Partners portfolio company Axera announced a partnership with Aptiv, a global leader in automotive and mobility technology, to collaborate on advanced driver-assistance systems (ADAS). Building on existing mass-production projects, Aptiv will develop a next-generation forward-facing intelligent camera product and supporting ADAS system solution based on Axera's self-developed latest-generation high-performance, low-power ADAS chip, the M57. The solution has already secured a mass-production design win for a leading Chinese new-force OEM's Europe-bound export models.
Going forward, Axera and Aptiv will deepen their collaboration to jointly explore new technologies, products, and applications in the ADAS space. The two parties expect to expand their partnership based on Axera's series of automotive chips, working together to drive continuous upgrades in ADAS technology.
06/
Axera Partners with STRADVISION to Build Global ADAS Solutions
Recently, Qiming Venture Partners portfolio company Axera formally signed a strategic cooperation agreement with STRADVISION, an industry-leading AI visual perception technology company. The two parties will leverage their respective core technical strengths to jointly develop ADAS solutions for the global automotive market.
STRADVISION will take the lead in developing on Axera's M57 series chips, adapting its highly competitive visual perception solution "SVNet" to the platform. Axera will provide comprehensive technical support and a complete toolchain. As the collaboration deepens, the two parties will also conduct adaptation development on additional Axera automotive chip platforms, aiming to provide global automakers with diversified ADAS solutions.
07/
Axera and MAXIEYE Deepen Strategic Cooperation
Recently, Qiming Venture Partners portfolio company Axera signed an agreement to deepen strategic cooperation with MAXIEYE (Zhijia Automotive Technology (Ningbo) Co., Ltd.). Going forward, the two parties will achieve stronger strategic alignment in technology and product development, market expansion, and other areas, jointly developing the global ADAS market to deliver better mobility experiences for more customers and users.
Axera will provide full-stack support from chip R&D to toolchain development, helping MAXIEYE improve the deployment efficiency of its MAXIPILOT® ADAS system. MAXIEYE will also leverage its QingCloud BEV deep learning architecture and Haishi data intelligence system to achieve rapid algorithm adaptation and optimized AI model closed loops, delivering high-quality system-level solutions.
08/
Polestones and Weiqiao Pioneering Group Formally Establish Lightweight Joint Laboratory
Recently, Qiming Venture Partners portfolio company Polestones and Weiqiao Pioneering Group jointly established the "Weiqiao-Polestones Automotive Lightweight Joint Laboratory" in Suzhou, Jiangsu, marking a new phase in their strategic cooperation. The laboratory's establishment not only signifies the two parties' joint push for innovation and commercialization of lightweight technology, but will also play an active role in cultivating talent for the materials and automotive fields, driving vigorous industry development.
The joint laboratory will focus on three areas — materials innovation, process upgrading, and structural design — building a full-lifecycle technical system to inject new vitality into Polestones' next-generation products. Under the joint R&D plan, the next-generation product's body aluminum content will increase to 50%, body weight will decrease by 15%, body torsional rigidity will improve by 11%, and driving range will increase by 10%. Meanwhile, the next-generation product's chassis components will incorporate world-leading anti-fatigue automotive cast aluminum alloy jointly developed by both parties.
09/
Trina Solar and Shangyue Technology Reach Cooperation
Recently, Trina Solar Co., Ltd. ("Trina Solar") and Qiming Venture Partners portfolio company Shangyue formally held a procurement mall project kickoff meeting.
In recent years, as Trina Solar's business has rapidly expanded, its procurement management has faced challenges including fragmented suppliers, difficult data governance, and insufficient integration of critical processes. The procurement mall project established through this cooperation aims to address Trina Solar's procurement pain points from multiple dimensions — demand side, management side, IT side, and procurement side — achieving cost reduction and efficiency improvement while providing strong data support for business decision-making.
10/
China Hospitality Association and Yunji Technology Release World's First Officially Certified Hotel AI Agent Service Solution
At the 14th China Hotel Culture Festival and China Hotel Industry High-Quality Development Conference, Qiming Venture Partners portfolio company Yunji Technology and the China Hospitality Association jointly released the world's first officially certified hotel AI agent service solution. This breakthrough not only advances the intelligent upgrading of China's hotel industry, but also showcases to the world the outstanding practice of AI agent technology in the hotel sector.
Yunji Technology CEO Li Quanyin stated at the conference that Yunji's AI agent, through "AI + robots + scenario-based services," has created a hotel service and management agent in hotels spanning from guest needs collection, human-machine collaborative dispatching, digital employee intelligent assistants, to service efficiency monitoring and management optimization, empowering the full hotel service process. The upgrade of AI agents will accelerate the arrival of a new world surrounded by AI. Existing innovation paradigms, organizational models, work forms, and lifestyles may all undergo comprehensive reconstruction.
11/
DeepWise and Yibin University Among Others Hold Bohr Research Space Station Signing Ceremony
At the "AI Empowerment, Intelligence Creating the Future" Young Top Scientists Yibin Seminar, Qiming Venture Partners portfolio company DeepWise held a signing ceremony for the Bohr Research Space Station with Yibin University, Xihua University Yibin Campus, Sichuan University of Science & Engineering, Chengdu Technological University Yibin Campus, Chengdu International Studies University Yibin Campus, and Yibin Libao New Materials Co., Ltd.
The Bohr Research Space Station is DeepWise's flagship research platform, developed by the global leader in AI for Science. As the world's first AI research platform covering the full pipeline from "literature review — computational modeling — experimentation — multidisciplinary collaboration," the Bohr Research Space Station is centered around the newly upgraded Science Navigator (SN), designed to help scientists return to what truly matters in research. The platform features hundreds of leading algorithms and AI for Science large models developed independently by DeepWise, along with abundant computing power, enabling comprehensive support for scientific computing scenarios. Closely following the model of "industry-education integration, innovation-driven development," it drives deep integration of AI technology into Yibin's educational research and industrial upgrading.
R&D Progress
01/
Gan & Lee Pharmaceuticals Hosts National Investigator Meetings for GZR4-T2D-301 and GZR4-T2D-303 Clinical Trials
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) successfully held two national investigator meetings in Tianjin and Changsha, Hunan, focusing on Phase 3 clinical trial programs for GZR4-T2D-301 and GZR4-T2D-303 respectively. Through a hybrid online-offline format, the meetings drew over 220 clinical investigators from more than 150 hospitals nationwide to discuss R&D progress and execution strategies for the ultra-long-acting weekly insulin formulation GZR4 injection.
Gan & Lee Pharmaceuticals' independently developed GZR4 injection is an ultra-long-acting weekly insulin formulation expected to provide smoother glucose-lowering effects with less day-to-day blood glucose variability. Administered via subcutaneous injection once weekly, GZR4 is anticipated to help diabetes patients overcome injection barriers, initiate insulin therapy earlier, optimize long-term diabetes management, and improve quality of life. Early clinical study results indicate that GZR4 injection reduced HbA1c in Type 2 diabetes patients comparably to or better than insulin degludec. The global development of GZR4 injection has now entered Phase 3 clinical trials.
02/
Gan & Lee Pharmaceuticals' GZR102 Injection Receives Clinical Trial Approval in China
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its wholly-owned subsidiary, Gan & Lee Pharmaceuticals Shandong Co., Ltd., has received implied approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for its independently developed GZR102 injection for the indication of Type 2 diabetes mellitus (T2DM).
This drug is a fixed-ratio combination (FRC) weekly formulation composed of Gan & Lee Pharmaceuticals' independently developed ultra-long-acting insulin GZR4 and ultra-long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) bofanglutide (GZR18). The individual components — GZR4 injection and bofanglutide injection — have both undergone adequate dose exploration in Phase 2 clinical trials for T2DM, demonstrating excellent glucose-lowering efficacy on top of favorable safety and tolerability profiles. The global development of both individual components has now advanced to Phase 3 clinical studies.
03/
Zai Lab to Present Latest Phase 1 Clinical Data for ZL-1310 at ASCO Annual Meeting
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) announced that updated data from its ongoing global Phase 1a/1b clinical study (NCT06179069) will be presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The updated results will include data from additional patients as well as follow-up information from the ongoing ZL-1310 study in patients with extensive-stage small cell lung cancer (ES-SCLC) who have received at least one prior platinum-containing chemotherapy regimen.
DLL3 is an antigen overexpressed in multiple neuroendocrine tumors, including SCLC, and is typically associated with poor clinical prognosis. ZL-1310 comprises a humanized anti-DLL3 monoclonal antibody conjugated to a novel camptothecin derivative (a topoisomerase 1 inhibitor) as its payload. Designed using the novel ADC technology platform TMALIN®, which leverages the tumor microenvironment to overcome challenges encountered by first-generation ADC therapies. ZL-1310 received Orphan Drug Designation from the FDA in January 2025, underscoring recognition of its potential for treating SCLC patients.
04/
Zai Lab's Repotrectinib sNDA Accepted and Upgraded to CSCO Category 1 Recommendation
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) announced that China's National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions, who have locally advanced, metastatic, or surgically resectable disease that would likely result in severe morbidity, and who have progressed following prior treatment or have no satisfactory alternative treatment options.
Additionally, in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines for Non-Small Cell Lung Cancer, repotrectinib has been upgraded to a Category 1 recommendation for first-line and second-line treatment of Stage IV ROS1 fusion-positive non-small cell lung cancer.
05/
Antengene to Present Latest Clinical Research Results for ATG-037 and ATG-008 at ASCO Annual Meeting
Recently, Qiming Venture Partners portfolio company Antengene (06996.HK) announced it will present the latest clinical research results for its CD73 small molecule inhibitor ATG-037 and mTORC1/2 small molecule inhibitor ATG-008 in poster form at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Previously, Antengene entered into a global clinical collaboration with Merck & Co. to jointly conduct the Phase 1/1b STAMINA-01 study. The study is evaluating ATG-037 in combination with Merck & Co.'s PD-1 inhibitor KEYTRUDA® (pembrolizumab), and has achieved encouraging preliminary efficacy in anti-PD-1-resistant melanoma and non-small cell lung cancer (NSCLC) patients. The dose optimization and expansion phases of this study are currently progressing smoothly in China and Australia.
Corporate Development
UBTECH to Establish Xingzhe Tiangong Robotics Wholly-Owned Subsidiary in Beijing Yizhuang
Recently, Qiming Venture Partners portfolio company UBTECH (09880.HK) announced it will establish Xingzhe Tiangong Robotics as a wholly-owned subsidiary in Beijing Yizhuang, responsible for the full commercialization and global sales of its Walker series, Tiangong series, and Tiangong Xingzhe (research and education edition) humanoid robots.
This follows UBTECH's earlier collaboration with the Beijing Humanoid Robot Innovation Center to launch Tiangong Xingzhe, a full-size research and education humanoid robot platform, representing another major step forward.
Product Launches
01/
Roborock Launches Z1 MAX Washer-Dryer Set Series
and M1S Compact Washer-Dryer Series
Recently, Qiming Venture Partners portfolio company Roborock (688169.SH) launched the Z1 MAX washer-dryer set series and the M1S compact washer-dryer series.
The Z1 MAX series inherits Roborock's classic GloScreen™ hidden door design with a disruptive full-screen display. The product has earned dual green-label certification from The Woolmark Company, making it safe to wash and dry wool; Roborock's proprietary ZeoHyb™ molecular sieve technology and ultra-efficient heat pump drying system ensure low-temperature, high-efficiency performance; equipped with TriadSwift™ ultra-efficient triple inverter technology, the drying speed is improved by 23% while energy consumption is reduced by 24%; Roborock FineFoam® ultra-clean mousse wash achieves a 1.2 cleanliness ratio. The SoftVibe™ "new dry cleaning" garment care system delivers professional-grade fabric protection.
The M1S compact washer-dryer series features Roborock FineFoam® ultra-clean mousse wash for water, time, and energy savings. The product is equipped with Roborock's self-developed variable-temperature stain wash function capable of removing seven-day-old blood stains; the photon water sterilization system effectively eliminates HPV 16, achieving 99.99% bacteria, virus, allergen, and mite removal.
02/
Insta360 Releases New Flagship 8K 360 Camera X5
Recently, Qiming Venture Partners portfolio company Insta360 released its new flagship 8K 360 camera, the X5. The X5 delivers impressive upgrades: the sensor has been upgraded to 1/1.28 inches, a 144% increase in area; alongside a 5nm AI chip, two dedicated imaging chips have been added, bringing 8K ultra-high-definition 360 footage; a more rugged 360 lens with 100% improved drop resistance and a user-replaceable design; 15-meter waterproofing without a case, 185-minute battery life, and 80% fast charging in 20 minutes; equipped with Insta360's self-developed FlowState stabilization technology and a new microphone wind shield, fully emphasizing its action performance.
As an industry leader, Insta360 continues to lower the barrier to 360 imaging and build a creative ecosystem. The X5 adds a "dynamic tracking" mode that outputs flat videos straight after shooting without post-editing, while preserving the original 360 footage; Insta360's app has been completely redesigned with multiple AI features including "AI View" and "AI Magician" to help auto-generate clips, making 360 creation easier; "Insta360+ Cloud Service" integrates cloud storage, sharing, playback, editing, and export, enhancing the 360 camera user experience.
03/
Axera Unveils Globalization Strategy and
New Generation Automotive Chip Product M57 Series
Recently, Qiming Venture Partners portfolio company Axera made its appearance at 2025 Shanghai International Auto Show, unveiling its globalization strategy and new generation automotive chip product M57 series under the theme "Born Extraordinary, Intelligence for the World," while reaching deep cooperation with industry partners.
The Axera M57 series achieves comprehensive performance upgrades over its predecessor: the self-developed Axera Tongyuan NPU delivers 10 TOPS of computing power with native mixed-precision support and BEV algorithm compatibility; the self-developed Axera Zhimou AI-ISP, which enables more powerful assisted driving performance, has been optimized for automotive scenarios to deliver high-definition image quality under various extreme lighting conditions, with low-latency characteristics providing reliable input for subsequent planning and control systems. Additionally, the M57 integrates an MCU with a built-in safety island, enabling ASIL-B and ASIL-D level functional safety at the chip level to meet stringent domestic and international regulatory requirements. On power consumption, the M57 performs equally well, with power draw not exceeding 3.5W at 125°C junction temperature, accommodating both electric and gasoline vehicle needs and truly enabling "intelligence for all powertrains." Leveraging its accumulated mass production experience, the M57 is application-ready upon release and can be paired with various mature assisted driving solutions.
At the launch event, Axera announced the full activation of its diversified integrated strategy encompassing "localization, globalization, scaling, and high-end advancement." Axera's automotive products now cover a complete matrix from entry-level to high-end. Currently, the company serves numerous automakers with cumulative shipments exceeding several hundred thousand units.
04/
StepFun Releases and Open-Sources Image Editing
Large Model Step1X-Edit
Recently, Qiming Venture Partners portfolio company StepFun officially released and open-sourced its image editing large model Step1X-Edit, achieving state-of-the-art performance among open-source models. With total parameters of 19B (7B MLLM + 12B DiT), the model features three key capabilities: precise semantic parsing, identity consistency preservation, and high-precision regional control; it supports 11 categories of high-frequency image editing tasks including text replacement, style transfer, material transformation, and portrait retouching.
Step1X-Edit marks the first deep integration of MLLM and DiT within the open-source ecosystem, achieving substantial improvements in editing precision and image fidelity. On the newly released image editing benchmark GEdit-Bench, Step1X-Edit leads all existing open-source models across semantic consistency, image quality, and composite score metrics, rivaling GPT-4o and Gemini 2.0 Flash.
05/
AmoyDx Human 10-Gene Mutation Combined Detection Kit
Approved in China as Companion Diagnostic for Rybrevant®
Recently, Qiming Venture Partners portfolio company AmoyDx (300685.SZ) had its Human 10-Gene Mutation Combined Detection Kit (reversible terminator sequencing) approved in China as a companion diagnostic for Rybrevant® (amivantamab injection), for reliable detection of EGFR exon 20 insertion mutations in non-small cell lung cancer patients to support clinical treatment decisions.
The AmoyDx Human 10-Gene Mutation Combined Detection Kit is used for qualitative detection of key oncogenic driver gene alterations in non-small cell lung cancer and colorectal cancer patients, covering ten clinically relevant genes: EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET. Among these, EGFR, ALK, ROS1, and KRAS have already been approved as companion diagnostic biomarkers for multiple targeted therapies. With this new approval for the EGFR biomarker companion diagnostic indication, comprehensive tumor molecular profiling and individualized treatment strategies will be further advanced.
06/
M20 Genomics Launches Standardized Downstream Analysis Tools
Recently, Qiming Venture Partners portfolio company M20 Genomics rolled out a comprehensive upgrade to its VITAseer® software and data platform. Following the successful release of VITAbasic v1.4, M20 Genomics has now introduced two standardized downstream analysis tools: VITAprok v1.0 and VITAeuk v1.0.
By integrating its three core software components — VITAbasic, VITAprok, and VITAeuk — the VITAseer platform enables end-to-end analysis of both eukaryotic and prokaryotic single-cell transcriptomes, from raw data processing through biological pathway interpretation. The platform not only fills a gap in standardized analysis tools for microbial single-cell transcriptomics but also offers modular analytical workflows that deliver efficient, flexible solutions for complex sample projects.
Technology & Innovation
01/
WeRide Officially Launches "Wen Yuan Chu Xing" App
To better serve users across China, Qiming Venture Partners portfolio company and global autonomous driving technology leader WeRide (NASDAQ: WRD) has officially rebranded its mobility app from "WeRide Go" to "Wen Yuan Chu Xing" (文远出行), making it easier to discover and download. The updated app also debuts a new "scheduled ride" feature. Users can now search for and download "Wen Yuan Chu Xing" across major app stores to hail WeRide Robotaxi autonomous rides with a single tap, while also accessing real-time information on WeRide Robobus operations.
Currently, WeRide Robotaxi services cover Beijing Yizhuang and Guangzhou Huangpu. WeRide Robobus routes include: in Beijing, a shuttle between the P12 parking lot at Urban Green Heart Forest Park and Beijing City Library, plus a route between Haojiafu subway station and Beijing City Library; in Guangzhou, the Bio Island South Line and Autonomous Mobility Line 1; and in Nanjing, a holiday sightseeing tour and an Ecotech Island campus shuttle, among others.
Beyond its self-operated mobility platform, WeRide also partners with local operators worldwide to deliver Robotaxi and Robobus services.
02/
DeepWay Completes First Delivery to STO Express
Becoming China's First New-Energy Heavy-Duty Truck Brand Serving the Express Delivery Industry
Recently, Qiming Venture Partners portfolio company DeepWay held a delivery ceremony in Shanghai with STO Express for the first batch of 36 new-energy heavy-duty trucks. This marks the first-ever new-energy heavy-duty truck delivery ceremony in China's express delivery industry — a milestone with significant symbolic importance.
As a leading "new force" in the truck industry, DeepWay pioneered the integrated battery-chassis design, increasing cargo box volume by 9.6% and payload per trip by 1.3 tons compared to conventional "fuel-to-electric" conversions, substantially meeting the express industry's demand for large-volume cargo capacity. The distributed drive design achieves energy consumption as low as 1.15 kWh per kilometer in this delivery batch while ensuring extended range to effectively cover high-frequency, medium-to-long-haul intercity transport. Additionally, the vehicles feature dual thermal management systems and L2-level advanced driver-assistance systems, enabling stable operation from -30°C to 45°C, enhancing driving safety and battery stability — earning broad user recognition.
03/
Cornerstone Robotics Enables Remote Surgical Robot Demonstration by Leading Robotic Surgeon
Recently, leveraging the remote surgery dedicated network and surgical robot system of Qiming Venture Partners portfolio company Cornerstone Robotics, a robotic surgeon based in Hong Kong delivered an innovative remote medical education demonstration to medical students at The Chinese University of Hong Kong (Shenzhen) School of Medicine.
Since its founding, Cornerstone Robotics has maintained a commitment to independent innovation, assembling a world-class founding team and academic advisory network focused on surgical robot technology R&D, clinical application translation, and high-quality training system development. This remote surgical robot demonstration marks a new phase in Cornerstone Robotics' strategic partnership with The Chinese University of Hong Kong (Shenzhen) School of Medicine, successfully validating the innovative value of Cornerstone's robots in medical education while advancing the shared development of medical resources across China's Greater Bay Area — laying a stronger foundation for surgical robot teaching research, clinical translation, and industrialization.
04/
Fushoukang Hosts Shanghai's First Targeted Domestic Services Training Program
Recently, Shanghai's first targeted training program for domestic services — the Hongkou District "Skills Light the Way Forward" initiative — held its completion ceremony. The program was hosted by Zunhu Vocational Skills Training School, a subsidiary of Qiming Venture Partners portfolio company Fushoukang. All 25 trainees passed their assessments, achieving a 100% employment rate, with full placement scheduled for this week.
Beyond providing professional, systematic skills training, Zunhu Vocational Skills Training School leverages Fushoukang's self-developed "Professor Fu" online education platform to create a lifelong learning model combining pre-job training with ongoing workplace education, ensuring trainees' skills keep pace with industry development. Through the self-directed learning platform, trainees can engage in bite-sized online study on their own schedules. Fushoukang also conducts quarterly centralized training sessions for in-service skill enhancement, with hours varying by topic. Subsequent assessments cover both theory and practice, with results recorded in the proprietary platform as valid references for employees' career advancement pathways.
05/
Bailinke Debuts at 24th China Biological Products Conference
Releases Antibody Bioprocessing and Application Cases
At the 24th China Biological Products Conference (CBioPC), Qiming Venture Partners portfolio company Bailinke showcased its comprehensive "Made in China" solutions covering the full biopharmaceutical workflow from development to production. The company also hosted a satellite symposium themed "Smart Antibody Manufacturing, Ecosystem Win-Win," officially releasing Antibody Bioprocessing and Application Cases, compiled by Bailinke's expert team — highlighting the company's latest explorations and practices in process standardization and ecosystem collaboration.
Antibody Bioprocessing and Application Cases systematically maps the key technical pathways in antibody drug development, covering critical nodes from cell line construction, culture processes, and purification workflows through commercial production. The publication emphasizes actionable recommendations and "Made in China" solutions, aiming to provide the industry with a practical, replicable reference guide.
06/
Tellgen Participates in 2025 Academic Summit of Labeled Immunoassay Professional Committee, China Association for Instrumental Analysis
At the 2025 Academic Summit hosted by the Labeled Immunoassay Professional Committee of the China Association for Instrumental Analysis, Qiming Venture Partners portfolio company Tellgen (300642.SZ), as an innovation pioneer in China's in vitro diagnostics field, presented multiple integrated solutions that combine innovative technologies with real clinical needs and have achieved full productization. Through new product launches and thematic presentations, Tellgen demonstrated its forward-looking vision in technological innovation and strategic planning.
Tellgen's highlight at the event was the third-generation T9 laboratory automation line, which redefines automation standards with its highly integrated, intelligently efficient, and flexibly compatible design.
In his presentation "Advances and Challenges in Thyroid Function Testing Laboratory Technologies," Professor Liu Chen'geng, director of the Clinical Laboratory at Beijing Anding Hospital, Capital Medical University, showcased the advantages of Tellgen's thyroid function testing projects and the performance of related reagents.
Company Honors
01/
Over 20 Qiming Venture Partners Portfolio Companies Named to 2025 China Future Unicorn Top 100 and Other Lists
At the 9th Annual Wanwu Growth Conference 2025, major lists were unveiled including the 2025 China Future Unicorn Top 100, Zhejiang Unicorn Company Rankings, Hangzhou Unicorn and Pre-Unicorn Company Rankings, and Hangzhou AI "Hidden Dragon" Map. These selections represent not only a deep dive into innovative enterprises but also an opportunity for investors to identify high-potential companies.
Qiming Venture Partners portfolio companies Houmo AI, Future Intelligent, Infinigence AI, Galaxy Universal, Caliber Medical, Cornerstone Robotics, Shize Biotech, and Inscinstech were named to the China Future Unicorn Top 100. Axera, Tongdun Technology, and WeDoctor received Zhejiang Unicorn honors; Caliber Medical and Yunqi Technology were named to the Zhejiang Future Unicorn Top 100; and BrightOcular made the Zhejiang Seed Unicorn Top 100. Tongdun Technology and WeDoctor were recognized as Hangzhou Unicorns; while Boner Orthopedics, GlorBio, AusperBio, HaisMind, Caliber Medical, ZD Medical, NovaWatson, Yunqi Technology, Spēs, and Wow Xiaoya were named Hangzhou Pre-Unicorns. Yunqi Technology, Buming Technology, Tongdun Technology, and Caliber Medical were included in the Hangzhou AI "Hidden Dragon" Map.
02/
DeepWise Founder Linfeng Zhang Wins Beijing Science and Technology Award — Outstanding Young Zhongguancun Award
The Beijing Science and Technology Awards were recently announced, honoring outstanding individuals and organizations in the scientific community. Linfeng Zhang, founder and chief scientist of Qiming Venture Partners portfolio company DeepWise and president of the AI for Science Institute, Beijing, received the 2024 Outstanding Young Zhongguancun Award, underscoring the tremendous potential of AI for Science.
Zhang has dedicated his career to interdisciplinary research at the intersection of AI and science, with extensive contributions in machine learning, computational physics and chemistry, and materials and drug design. His work has repeatedly pushed disciplinary boundaries, establishing him as a leading figure in the AI-science convergence. He led the development of the Deep Potential (DeePMD) algorithm, which accelerated molecular dynamics simulations by a factor of 1,000 and solved the "curse of dimensionality" that plagued traditional quantum mechanical calculations — winning the Gordon Bell Prize in 2020, the highest honor in high-performance computing. Nature hailed this achievement as "a milestone in computational science," and it was selected among China's Top 10 Scientific Advances. To date, Zhang has published nearly 100 papers in top-tier journals including Nature and Science, with cumulative citations exceeding 10,000, and has been named to Stanford's World's Top 2% Scientists list for three consecutive years. In March 2025, Zhang and collaborators released Uni-3DAR, a framework that unifies 3D structure generation and understanding through autoregressive next-token prediction. Uni-3DAR uses autoregression to unify the micro and macro 3D worlds, outperforming diffusion models by 256% with 21.8× faster inference — the world's first scientific foundation model of its kind.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Funding & Updates Vol. 14, 2025
Qiming Stars | Zoyi Tech Zhang Chao: Using AI Doctors to Fill the "Blank Zones" of Healthcare
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.